Market capitalization | $261.02m |
Enterprise Value | $208.79m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.63 |
P/S ratio (TTM) P/S ratio | 3.29 |
P/B ratio (TTM) P/B ratio | 2.78 |
Revenue growth (TTM) Revenue growth | 22.34% |
Revenue (TTM) Revenue | $79.30m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a ProLung Inc forecast:
6 Analysts have issued a ProLung Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 79 79 |
22%
22%
|
|
Gross Profit | 59 59 |
23%
23%
|
|
EBITDA | -55 -55 |
7%
7%
|
EBIT (Operating Income) EBIT | -56 -56 |
10%
10%
|
Net Profit | -57 -57 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Steven Williamson |
Employees | 279 |
Founded | 1995 |
Website | www.pulmonx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.